Education
About Us
Working with TipRanks
Follow Us
Immix Biopharma, Inc. (IMMX)
NASDAQ:IMMX
RESEARCH TOOLSreports
IMMX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.26 - $3.13
Previous Close$2.25
Volume74.23K
Average Volume (3M)54.48K
Market Cap
$46.57M
Enterprise ValueN/A
Total Cash (Recent Filing)$17.68M
Total Debt (Recent Filing)$1.07M
Price to Earnings (P/E)―
Beta1.68
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.79
Shares Outstanding27,722,109
10 Day Avg. Volume53,377
30 Day Avg. Volume54,475
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-3.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$7.00Price Target Upside334.78% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsUpdated results from the NEXICART-1 trial show NXC-201 elicited a 94% overall response rate (ORR) and a 75% complete response (CR) rate in 16 patients.
Market PotentialAnalysts forecast peak global NXC-201 sales of approximately $525M, given the lack of FDA-approved agents for relapsed/refractory AL amyloidosis and NXC-201's initial clinical data.
Regulatory MilestonesThe FDA granted RMAT designation to NXC-201, which is being evaluated in NEXICART-2 trial for the treatment of relapsed/refractory AL Amyloidosis.
Bears Say
Safety ConcernsRisks for Immix Biopharma include potential safety concerns, manufacturing challenges, and competition from other clinical agents.
---
Ownership Overview
40.45% Insiders
3.17% Mutual Funds
6.23% Other Institutional Investors
47.57% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IMMX FAQ
What was Immix Biopharma, Inc.’s price range in the past 12 months?
Immix Biopharma, Inc. lowest stock price was $1.26 and its highest was $3.13 in the past 12 months.
What is Immix Biopharma, Inc.’s market cap?
Immix Biopharma, Inc.’s market cap is $46.57M.
When is Immix Biopharma, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Immix Biopharma, Inc.’s earnings last quarter?
Currently, no data Available
Is Immix Biopharma, Inc. overvalued?
According to Wall Street analysts Immix Biopharma, Inc.’s price is currently Undervalued.
Does Immix Biopharma, Inc. pay dividends?
Immix Biopharma, Inc. does not currently pay dividends.
What is Immix Biopharma, Inc.’s EPS estimate?
Immix Biopharma, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Immix Biopharma, Inc. have?
Immix Biopharma, Inc. has 27,722,109 shares outstanding.
What happened to Immix Biopharma, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Immix Biopharma, Inc.?
Currently, no hedge funds are holding shares in IMMX
---
Immix Biopharma, Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.00 (334.78% Upside)
$7.00 (334.78% Upside)
Hedge Fund Trend
Decreased
By 27.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $104.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 4.5%
Last 30 Days ▼ 4.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-44.86%
12-Months-Change
Fundamentals
Return on Equity
-145.76%
Trailing 12-Months
Asset Growth
15.17%
Trailing 12-Months
Company Description
Immix Biopharma, Inc.
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.
---
IMMX Stock 12 Month Forecast
Average Price Target
$7.00
▲(334.78% Upside)
Technical Analysis
Mersana Therapeutics
―
―
Reviva Pharmaceuticals Holdings
―
Milestone Pharmaceuticals
―
Medicus Pharma Ltd
―
Best Analysts Covering IMMX
1 Year
1 Year Success Rate
1/5 ratings generated profit
1 Year Average Return
-13.22%
reiterated a buy rating 2 months ago
Copying Robert Burns's trades and holding each position for 1 Year would result in 20.00% of your transactions generating a profit, with an average return of -13.22% per trade.
---